![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ondine Biomed | LSE:OBP | London | Ordinary Share | CA68234M1068 | COM SHS NPV |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 18.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMOBP Ondine Announces Share Consolidation and Name Change FOR: ONDINE BIOPHARMA CORPORATION TSX, AIM SYMBOL: OBP October 11, 2010 Ondine Announces Share Consolidation and Name Change VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 11, 2010) - Ondine Biopharma Corporation (TSX:OBP)(AIM:OBP) (the "Company") today announced that the Company has received Toronto Stock Exchange acceptance and will proceed with the consolidation of all of its issued and outstanding common shares on the basis of fifteen (15) "old" common shares for one (1) "new" common share (the "Consolidation") and the name change from "Ondine Biopharma Corporation" to "Ondine Biomedical Inc.". Fractional shares remaining after giving effect to the Consolidation will be cancelled, such that shareholdings of each shareholder will be rounded down to the nearest whole number of post- consolidation common shares. The shares of the Company will commence trading on the TSX and on the AIM Market of the London Stock Exchange on a consolidated basis under the new name "Ondine Biomedical Inc." at the opening of trading on Thursday, October 14, 2010. The CUSIP number for the Company's post-consolidation common shares is 68234M106. The Company's trading symbol, OBP, will not change. About Ondine Biopharma Corporation Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing leading edge products utilizing its patented light-activated technology, primarily for the Hospital Acquired Infection (HAI) market. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development laboratory in Bothell, Washington, USA. For additional information, please visit the Company's website at: www.ondinebio.com. -30- FOR FURTHER INFORMATION PLEASE CONTACT: Ondine Biopharma Corporation Carolyn Cross Chairman and Chief Executive Officer (604) 669-0555 ccross@ondinebiopharma.com www.ondinebio.com OR Canaccord Genuity Limited Nominated Adviser Ryan Gaffney +4420 7050 6500 The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. Ondine Biopharma Corporation
1 Year Ondine Biomed Chart |
1 Month Ondine Biomed Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions